Pegloticase is a pegylated, recombinant uricase (urate-oxidase) FDA-approved in 2010 for its use in the management of chronic gout refractory to standard therapy in adult patients.

Pegloticase's safety and efficacy were assessed in two replicate multination, six-month randomized, double-blind, placebo-controlled clinical trials.

**FDA Approved Use**

- Chronic gout (refractory to conventional therapy)